Evidence map›Paper›PMID 36615835›Full record

ArticleNutrients2022

Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.

Nouf Aljobaily, Kelsey Krutsinger, Michael J Viereckl, Raznin Joly, Bridger Menlove, Brexton Cone, Ailaina Suppes, Yuyan Han

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nouf AljobailyDivision of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA.
Kelsey KrutsingerDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.ORCID 0000-0002-9588-6144
Michael J VierecklDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.
Raznin JolyDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.
Bridger MenloveDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.ORCID 0000-0001-8890-0115
Brexton ConeDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.
Ailaina SuppesDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.
Yuyan HanDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.ORCID 0000-0002-9982-9286
University of Northern Colorado · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-Alcoholic Steatohepatitis (NASH) is the progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD). NASH is distinguished by severe hepatic fibrosis and inflammation. The plant-derived, non-psychotropic compound cannabigerol (CBG) has potential anti-inflammatory effects similar to other cannabinoids. However, the impact of CBG on NASH pathology is still unknown. This study demonstrated the therapeutic potential of CBG in reducing hepatic steatosis, fibrosis, and inflammation.

methods8-week-old C57BL/6 male mice were fed with methionine/choline deficient (MCD) diet or control (CTR) diets for five weeks. At the beginning of week 4, mice were divided into three sub-groups and injected with either a vehicle, a low or high dose of CBG for two weeks. Overall health of the mice, Hepatic steatosis, fibrosis, and inflammation were evaluated.

resultsIncreased liver-to-body weight ratio was observed in mice fed with MCD diet, while a low dose of CBG treatment rescued the liver-to-body weight ratio. Hepatic ballooning and leukocyte infiltration were decreased in MCD mice with a low dose of CBG treatment, whereas the CBG treatment did not change the hepatic steatosis. The high dose CBG administration increased inflammation and fibrosis. Similarly, the expression of cannabinoid receptor (CB)1 and CB2 showed decreased expression with the low CBG dose but not with the high CBG dose intervention in the MCD group and were co-localized with mast cells. Additionally, the decreased mast cells were accompanied by decreased expression of transforming growth factor (TGF)-β1.

conclusionsCollectively, the low dose of CBG alleviated hepatic fibrosis and inflammation in MCD-induced NASH, however, the high dose of CBG treatment showed enhanced liver damage when compared to MCD only group. These results will provide pre-clinical data to guide future intervention studies in humans addressing the potential uses of CBG for inflammatory liver pathologies, as well as open the door for further investigation into systemic inflammatory pathologies.

Indexed as

Choline DeficiencyNon-alcoholic Fatty Liver DiseaseAnimalsBody WeightCannabinoidsCholineDietFibrosisHumansInflammationLiverLiver CirrhosisMethionineMiceMice, Inbred C57BLRacemethioninecannabigerolCannabinoidsCholineMethionineRacemethionineReceptors, Cannabinoidcannabigerolfibrosisinflammationmethionine-choline-deficient dietnon-alcoholic fatty liver diseasenon-alcoholic steatohepatitis

Identifiers

PMID36615835
PMCPMC9823433
OpenAlexW4313471567

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.